Use of Activated Recombinant FVII in Spinal Surgery
| Status: | Completed |
|---|---|
| Conditions: | Orthopedic, Hematology |
| Therapuetic Areas: | Hematology, Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 1/14/2017 |
| Start Date: | July 2004 |
| End Date: | February 2006 |
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
This trial is conducted in the United States of America (USA). The purpose of this clinical
research trial is to understand how safe and effective Recombinant Activated FVII is for
reducing bleeding and blood transfusions in patients undergoing spinal fusion surgery.
research trial is to understand how safe and effective Recombinant Activated FVII is for
reducing bleeding and blood transfusions in patients undergoing spinal fusion surgery.
Inclusion Criteria:
- Elective spinal fusion surgery.
Exclusion Criteria:
- History of thrombotic disorders (myocardial infarction, deep vein thrombosis,
pulmonary embolism, stroke, disseminated intravascular coagulation or peripheral
artery thrombosis)
- Any trauma within the last 3 months leading to hospitalization > 24 hours
- Angina or known coronary artery disease
We found this trial at
14
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials